阿托伐他汀片联合苯磺酸氨氯地平片治疗冠心病合并脑梗死的临床研究

Clinical trial of atorvastatin tablet combined with amlodipine besylate tablet in the treatment of coronary heart disease complicated with cerebral infarction

目的观察阿托伐他汀联合苯磺酸氨氯地平治疗冠心病合并脑梗死患者的临床疗效和安全性。方法入选我院收治的冠心病合并脑梗死患者120例,随机分为试验组和对照组,每组60例。对照组给予苯磺酸氨氯地平5mg·d^(-1),口服;试验组在对照组的基础上给予阿托伐他汀10 mg·d^(-1),口服。2组均治疗4周。比较2组患者的临床疗效及安全性。结果试验组和对照组的有效率分别为91.67%(55例/60例),75.00%(45例/60例),差异有统计学意义(P<0.05)。治疗后,试验组的平均心率、室上性心律失常和室性心律失常计数分别为(77.64±5.24),(124.90±12.68),(79.67±10.22)times·min^(-1),对照组分别为(81.37±4.58),(137.22±16.60),(117.23±15.36)times·min^(-1),差异均有统计学意义(均P<0.05)。2组患者药物不良反应主要表现为心悸、肝功能变化和头晕,试验组和对照组药物不良反应发生率分别为1.67%(1例/60例),11.67%(7例/60例),差异有统计学意义(P<0.05)。结论阿托伐他汀联合苯磺酸氨氯地平治疗冠心病合并脑梗死疗效较好,且药物不良反应发生率低。

Objective To investigate the clinical efficacy and safety of atorvastatin combined with amlodipine besylate in the treatment of coronary heart disease complicated with cerebral infarction. Methods A total of 120 cases of coronary heart disease patients with cerebral infarction in our hospital were randomly divided into treatment group and control group,60 cases in each group. Patients in control group were given amlodipine besylate 5 mg·d^-1,orally. Patients in treatment group were given atorvastatin statins,10 mg·d^-1,orally on the basis of control group. All patients were treated for 4 weeks. After treatment,the clinical efficacy and safety were compared between the two groups of patients.Results After treatment,total effective rates in treatment group and control group were 91.67%（ 55 cases/60 cases） and 75.00%（ 45 cases/60 cases）,with significant differences（P〈0.05）. After treatment,the mean heart rate,supraventricular arrhythmias and ventricular arrhythmia counts in treatment group were（77.64 ± 5.24）,（ 124.90 ± 12.68）,（ 79.67 ± 10.22） times·min^-1,had significance with those in control group,which were（ 81.37 ± 4.58）,（ 137.22 ± 16.60）,（ 117.23 ± 15.36） times·min^-1（ P〈0.05）. The main symptoms of adverse drug reactions in two groups were heart palpitations,liver function change,and dizziness. The incidence of adverse drug reactions in treatment group and control group were 1.67%（ 1 case/60 cases）,11. 67%（7 cases/60 cases）,with significant difference（P〈0.05）.Conclusion Atorvastatin combined with amlodipine besylate have obvious clinical efficacy and low incidence of adverse drug reactions.